Announcement • 17h

Galderma Announces Positive Topline Results for Restylane Volyme in Correction of Moderate-To-Severe Temple Hollowing in Chinese Patients

Galderma announced positive topline results from a study of Restylane Volyme for the correction of moderate-to-severe temple hollowing in 162 patients in China. The study met its primary endpoint, demonstrating the effectiveness and safety of Restylane Volyme versus a no-treatment control, while also achieving high patient and investigator satisfaction. Powered by diverse NASHA®, NASHA HD™, and OBT™ technologies, Restylane offers gels with the highest firmness to the highest flexibility, enabling personalized treatments that deliver structural support, natural-looking results, and a healthy glow. Restylane Volyme is a moderately soft and flexible gel made with OBT that distributes within the tissue to offer natural-looking results, helping to soften temple hollowing, restore facial balance, and create a refreshed appearance. With a dual-layer patent-pending technique leveraging both needle and cannula, Restylane Volyme enables healthcare professionals to provide precise, customized, and safe product placement in line with each patient’s aesthetic goals. The volume of the temples can diminish with age, which can disrupt facial balance and harmony, and contribute to a tired, sunken, and aged appearance. These facial changes can be accelerated in people undergoing medication-driven weight loss, a phenomenon which has increased rapidly in recent years. Following the launch of Restylane Volyme in China for the treatment of the mid-face region, this study provides new evidence supporting its effectiveness and safety for correction of temple hollowing, in a market where there are currently limited options. In this randomized, evaluator-blinded study, 162 adults were recruited across six sites in China and were split 2:1 into two groups; the Restylane Volyme treatment group or the no treatment control group. Results showed that for patients in the Restylane Volyme group: 94.4% of patients demonstrated at least 1-grade improvement in temple hollowing, from baseline, in both temples at Month 6 after last treatment, compared to just 2.0% in the control group at Month 6 after baseline. Blinded-evaluator Galderma Temple Volume Deficit Scale responder rates remained high through Month 12. 91.3% of patients showed improvement on the Global Aesthetic Improvement Scale for both temples through Month 12, according to the treating investigator. Patient satisfaction was high at Month 3 and remained consistently high, with more than 84% of patients satisfied with both the natural look and natural feel of their temples through Month 12. More than 90% said they would recommend the treatment to a friend, and over 86% would have the treatment again. Half of the participants felt comfortable returning to social engagement within 24 hours after initial treatment. Restylane Volyme was generally well tolerated, with no treatment-related serious adverse events and no granulomas. The Restylane portfolio offers a versatile range of HA gels that remain highly relevant in responding to today’s most significant aesthetic trends and needs. China is one of the fastest growing aesthetics markets worldwide and HA fillers are among the top 10 most-sold aesthetics products. This study highlights Galderma’s commitment to expand the availability of its Restylane portfolio to more patients and practitioners in China and exemplifies its continuing expansion in a growing and strategically significant market. Restylane HA treatments are designed differently to go beyond volumizing for natural-looking results. The HA is minimally modified and the innovative manufacturing process preserves its biocompatibility while creating individual products designed for a specific purpose. Powered by NASHA®, NASHA HD™, and OBT™ technologies, Restylane offers gels with the highest firmness to the highest flexibility, enabling personalized treatments that deliver structural support, natural-looking results, and a healthy glow. Trusted for almost three decades, the HA gels work in sync with skin for 100% natural-looking results. Approved indications vary by market.

Galderma Group AG Stock Price

GALD Share Price Performance

GALD Community Narratives

Rising Global Controls And Biosimilar Risks Will Squeeze Margins

GALD: Execution On New Aesthetic Launches And Margin Gains Will Sustain Upside

Aging Global Demand And Minimally Invasive Procedures Will Reinvent Aesthetics

GALD: Execution On New Aesthetic Launches And Margin Gains Will Sustain Upside

Rising Global Controls And Biosimilar Risks Will Squeeze Margins

Aging Global Demand And Minimally Invasive Procedures Will Reinvent Aesthetics

Trending Discussion

Recently Updated Narratives

GALD: Aesthetics Expansion And Nemluvio Will Drive Re Rating Potential

GALD: Elevated P E Will Likely Struggle If Injectable Aesthetics Disappoint

GALD: Aesthetics And Dermatology Execution Will Drive Future Re Rating Conviction

Snowflake Analysis

Galderma Group AG Key Details

About GALD

Recent GALD News & Updates

Restylane Volyme Delivers Positive China Results as Galderma Targets Expansion

Galderma Announces Positive Topline Results for Restylane Volyme in Correction of Moderate-To-Severe Temple Hollowing in Chinese Patients

GALD: Elevated P E Will Likely Struggle If Injectable Aesthetics Disappoint

Recent updates

Galderma Group AG Competitors

Novartis

Lonza Group

Sandoz Group